Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has received a consensus recommendation of “Buy” from the twenty-nine research firms that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty-two have issued a buy rating on the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $196.32.

A number of equities research analysts recently commented on VRTX shares. ValuEngine raised Vertex Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, June 2nd. BidaskClub cut Vertex Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Wednesday, June 6th. Argus set a $172.00 price objective on Vertex Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, June 12th. They noted that the move was a valuation call. Zacks Investment Research raised Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and set a $178.00 price objective for the company in a research note on Saturday, June 30th. Finally, JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Vertex Pharmaceuticals in a research note on Sunday, July 1st.

Shares of Vertex Pharmaceuticals stock opened at $175.80 on Friday. The company has a quick ratio of 3.55, a current ratio of 3.67 and a debt-to-equity ratio of 0.01. Vertex Pharmaceuticals has a 12 month low of $136.50 and a 12 month high of $186.44. The firm has a market cap of $45.75 billion, a P/E ratio of 219.75, a P/E/G ratio of 1.82 and a beta of 1.46.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings data on Wednesday, July 25th. The pharmaceutical company reported $0.94 EPS for the quarter, topping analysts’ consensus estimates of $0.40 by $0.54. Vertex Pharmaceuticals had a return on equity of 19.86% and a net margin of 15.84%. The business had revenue of $752.20 million during the quarter, compared to analysts’ expectations of $680.86 million. During the same period in the previous year, the firm earned $0.39 earnings per share. The firm’s quarterly revenue was up 38.2% compared to the same quarter last year. equities research analysts anticipate that Vertex Pharmaceuticals will post 2.48 earnings per share for the current fiscal year.

In other Vertex Pharmaceuticals news, EVP David Altshuler sold 2,125 shares of Vertex Pharmaceuticals stock in a transaction dated Tuesday, August 28th. The stock was sold at an average price of $181.89, for a total transaction of $386,516.25. Following the transaction, the executive vice president now directly owns 41,238 shares in the company, valued at $7,500,779.82. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Jeffrey M. Leiden sold 140,211 shares of Vertex Pharmaceuticals stock in a transaction dated Friday, June 22nd. The stock was sold at an average price of $160.00, for a total value of $22,433,760.00. Following the transaction, the chief executive officer now owns 297,260 shares in the company, valued at $47,561,600. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 205,790 shares of company stock worth $33,615,981. Corporate insiders own 0.75% of the company’s stock.

Several institutional investors have recently modified their holdings of VRTX. Renaissance Technologies LLC lifted its holdings in shares of Vertex Pharmaceuticals by 42.1% in the second quarter. Renaissance Technologies LLC now owns 4,050,617 shares of the pharmaceutical company’s stock valued at $688,443,000 after purchasing an additional 1,199,700 shares in the last quarter. Summit Trail Advisors LLC lifted its holdings in shares of Vertex Pharmaceuticals by 11,575.0% in the first quarter. Summit Trail Advisors LLC now owns 956,067 shares of the pharmaceutical company’s stock valued at $956,000 after purchasing an additional 947,878 shares in the last quarter. American Century Companies Inc. lifted its holdings in shares of Vertex Pharmaceuticals by 357.5% in the second quarter. American Century Companies Inc. now owns 1,125,428 shares of the pharmaceutical company’s stock valued at $191,278,000 after purchasing an additional 879,411 shares in the last quarter. Standard Life Aberdeen plc lifted its holdings in shares of Vertex Pharmaceuticals by 238.9% in the second quarter. Standard Life Aberdeen plc now owns 1,144,913 shares of the pharmaceutical company’s stock valued at $194,646,000 after purchasing an additional 807,086 shares in the last quarter. Finally, PointState Capital LP lifted its holdings in shares of Vertex Pharmaceuticals by 160.9% in the second quarter. PointState Capital LP now owns 779,200 shares of the pharmaceutical company’s stock valued at $132,433,000 after purchasing an additional 480,523 shares in the last quarter. Institutional investors own 93.43% of the company’s stock.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, develops medicines for serious diseases. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI (lumacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are homozygous for the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; KALYDECO (ivacaftor) for the treatment of patients with CF who have specific mutations in their CFTR gene, including the G551D mutation; and SYMDEKO (tezacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are F508del homozygous or who have 1 mutation that is responsive to tezacaftor/ivacaftor.

Featured Article: How to Use a Moving Average for TradingĀ 

Analyst Recommendations for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.